Compare Tango Therapeutics Inc. (TNGX) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Vanguard S&P 500 ETF — how do they compare? Tango Therapeutics Inc. trades at $22.2 (market cap $3.74B), while Vanguard S&P 500 ETF trades at $705.23 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 481.3× Tango Therapeutics Inc.'s market cap, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Vanguard S&P 500 ETF for 57 Days on average.
| TNGX | VOO | |
|---|---|---|
Market Cap | $3.74B | $1.80T |
Volume | 3,438,781 | 6,187,754 |
Sector | Health | Broad Market / Factor |
52-Week High | $32.90 | $716.17 |
52-Week Low | $7.50 | $580.93 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $2.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
VOO trades at $715.14 with minimal daily movement (-0.01, -0.0%). The ETF shows strong technical momentum with bullish moving averages and neutral oscillators, while trading near pivot point resistance. Recent news highlights VOO's role in long-term wealth building through S&P 500 exposure, with discussions on dividend strategies and recession resilience.
VOO offers diversified exposure to the S&P 500 with strong institutional backing. Key risks include market volatility and interest rate sensitivity, but its low-cost structure and broad market coverage provide stability. Short interest increased 46.9% in September (Defense World, 2026-10-03), warranting monitoring of bearish sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
